Xu Aimin, Wang Yu, Xu Jian Yu, Stejskal David, Tam Sidney, Zhang Jialiang, Wat Nelson M S, Wong Wai Keung, Lam Karen S L
Department of Medicine, University of Hong Kong, Hong Kong, China.
Clin Chem. 2006 Mar;52(3):405-13. doi: 10.1373/clinchem.2005.062463. Epub 2006 Jan 19.
Adipocyte fatty acid-binding protein (A-FABP) is traditionally thought to be a cytosolic fatty acid chaperone expressed in adipocytes. Mice with targeted disruption of the A-FABP gene exhibit a striking phenotype with strong protection from insulin resistance, hyperglycemia, and atherosclerosis. The clinical relevance of these findings remains to be confirmed.
We used tandem mass spectrometry-based proteomic analysis to identify proteins secreted from adipocytes and present in human serum. We measured serum A-FABP concentrations in 229 persons (121 men and 108 women; age range, 33-72 years), including 100 lean [body mass index (BMI) <25 kg/m2] and 129 overweight/obese individuals (BMI >25 kg/m2) selected from a previous cross-sectional study.
A-FABP was released from adipocytes and was abundantly present in human serum. Mean (SD) circulating concentrations of A-FABP were significantly higher in overweight/obese than in lean persons [32.3 (14.8) vs 20.0 (9.8) microg/L; P < 0.001]. Age- and sex-adjusted serum A-FABP concentrations correlated positively (P < 0.005) with waist circumference, blood pressure, dyslipidemia, fasting insulin, and the homeostasis model assessment insulin resistance index. Moreover, we observed a significant increase in A-FABP concentrations corresponding with increases in the number of components of the metabolic syndrome (P < 0.05).
A-FABP is a circulating biomarker closely associated with obesity and components of the metabolic syndrome, and measurement of serum concentrations of A-FABP might be useful for clinical diagnosis of obesity-related metabolic and cardiovascular disorders.
脂肪细胞脂肪酸结合蛋白（A-FABP）传统上被认为是一种在脂肪细胞中表达的胞质脂肪酸伴侣蛋白。A-FABP基因靶向破坏的小鼠表现出显著的表型，对胰岛素抵抗、高血糖和动脉粥样硬化具有强大的保护作用。这些发现的临床相关性仍有待证实。
我们使用基于串联质谱的蛋白质组学分析来鉴定脂肪细胞分泌并存在于人体血清中的蛋白质。我们测量了229人（121名男性和108名女性；年龄范围33 - 72岁）的血清A-FABP浓度，这些人选自之前的一项横断面研究，其中包括100名瘦人[体重指数（BMI）<25 kg/m²]和129名超重/肥胖个体（BMI>25 kg/m²）。
A-FABP从脂肪细胞中释放出来，并大量存在于人体血清中。超重/肥胖者的A-FABP平均（标准差）循环浓度显著高于瘦人[32.3（14.8）对20.0（9.8）μg/L；P<0.001]。经年龄和性别调整后的血清A-FABP浓度与腰围、血压、血脂异常、空腹胰岛素以及稳态模型评估胰岛素抵抗指数呈正相关（P<0.005）。此外，我们观察到A-FABP浓度随着代谢综合征组分数量的增加而显著升高（P<0.05）。
A-FABP是一种与肥胖和代谢综合征组分密切相关的循环生物标志物，测量血清A-FABP浓度可能有助于肥胖相关代谢和心血管疾病的临床诊断。
